Clinic
Community Health Development INC.
Community Health Development INC. was paid $2.82M by Medicaid between Feb 2018 and Dec 2024, across 54 billing codes. Its largest line is T1015, a visit at a community health center or clinic (one all-in rate) — 72% of everything it billed.
33Billing provider infoCOMMUNITY HEALTH DEVELOPMENT INC.
UVALDE, TX 78801
UVALDE, TX 78801
33aNPI1134102403assigned 11/21/2005
33bProvider typeFederally Qualified Health Center (FQHC)
28Total paid$2.82M
24GClaims51,408
24DCodes billed54
24AFirst – last monthFeb 2018 – Dec 2024
Compared with peers
Next to other Federally Qualified Health Center (FQHC) providers in Texas
Rank by total paid#71 of 248
Median peer was paid$796K
This provider vs. median3.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 65 | $7K | |
| 2019 | 114 | $5K | |
| 2020 | 2,320 | $139K | |
| 2021 | 13,303 | $686K | |
| 2022 | 13,693 | $700K | |
| 2023 | 13,996 | $814K | |
| 2024incomplete | 7,917 | $470K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 72% | 14,728 | 10,918 | $2.03M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11% | 8,321 | 7,262 | $311K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.7% | 2,895 | 2,550 | $105K |
| G0467 | Community health center visit, returning patientFederally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit | 2.8% | 2,881 | 2,409 | $78K |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 2.7% | 1,345 | 949 | $75K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.5% | 1,749 | 1,554 | $72K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.4% | 644 | 526 | $38K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 286 | 270 | $16K |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | <1% | 205 | 168 | $14K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 101 | 100 | $14K |
| 90837 | Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient | <1% | 128 | 91 | $11K |
| G0511 | Rural health clinic or federally qualified health center (rhc or fqhc) only, general care management, 20 minutes or more of clinical staff time for chronic care management services or behavioral health integration services directed by an rhc or fqhc practitioner (physician, np, pa, or cnm), per calendar month | <1% | 787 | 787 | $11K |
42 more codes
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 599 | $6K |
| CP004 | <1% | 523 | $5K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 71 | $4K |
| 80053 | Comprehensive metabolic panel | <1% | 1,645 | $4K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 821 | $4K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 55 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,351 | $3K |
| 80061 | Lipid panel | <1% | 1,230 | $3K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,639 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 901 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 465 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 464 | $2K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 154 | $2K |
| 81025 | <1% | 1,049 | $789.76 | |
| 92552 | <1% | 543 | $737.57 | |
| 90674 | <1% | 81 | $624.38 | |
| 81002 | <1% | 772 | $605.65 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 59 | $364.14 |
| 90686 | <1% | 40 | $328.46 | |
| 87510 | <1% | 284 | $312.52 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 13 | $235.84 |
| S4993 | Contraceptive pills for birth control | <1% | 25 | $163.10 |
| 87660 | <1% | 284 | $151.56 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 72 | $147.40 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 42 | $128.82 |
| 82043 | <1% | 117 | $126.36 | |
| 87480 | <1% | 284 | $121.64 | |
| 82570 | <1% | 129 | $117.45 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 72 | $111.75 |
| 84439 | <1% | 31 | $107.56 | |
| 85018 | <1% | 341 | $87.55 | |
| 3074F | 0% | 776 | $0.00 | |
| 3079F | 0% | 262 | $0.00 | |
| 3008F | 0% | 73 | $0.00 | |
| 3075F | 0% | 14 | $0.00 | |
| 90619 | 0% | 18 | $0.00 | |
| 99173 | 0% | 865 | $0.00 | |
| 3077F | 0% | 105 | $0.00 | |
| 3046F | 0% | 12 | $0.00 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 276 | $0.00 |
| 3078F | 0% | 769 | $0.00 | |
| 90621 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCASTANON, MAYELA (CHIEF EXECUTIVE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Community Health Development, INC. | Uvalde, TX | $539K |
| Community Health Development, INC | Leakey, TX | $269K |
| Community Health Development, INC | Camp Wood, TX | $186K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.